Tim Wilsdon is speaking during the conference in a session titled “Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements.”
For more information on this event, click here.
Key Health Care Antitrust and Competition Takeaways from ASHEcon 2025
Focusing on the intersection of academic research and litigation matters, Daniel Shack and Annabelle Fowler highlight key research developments and discussion...